Titre : Aurora kinases

Aurora kinases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Molecular Docking Simulation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Aurora kinases : Questions médicales les plus fréquentes", "headline": "Aurora kinases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Aurora kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-30", "dateModified": "2025-03-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Aurora kinases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protein-Serine-Threonine Kinases", "url": "https://questionsmedicales.fr/mesh/D017346", "about": { "@type": "MedicalCondition", "name": "Protein-Serine-Threonine Kinases", "code": { "@type": "MedicalCode", "code": "D017346", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Aurora kinase A", "alternateName": "Aurora Kinase A", "url": "https://questionsmedicales.fr/mesh/D064096", "about": { "@type": "MedicalCondition", "name": "Aurora kinase A", "code": { "@type": "MedicalCode", "code": "D064096", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.103.500" } } }, { "@type": "MedicalWebPage", "name": "Aurora kinase B", "alternateName": "Aurora Kinase B", "url": "https://questionsmedicales.fr/mesh/D064107", "about": { "@type": "MedicalCondition", "name": "Aurora kinase B", "code": { "@type": "MedicalCode", "code": "D064107", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.103.750" } } }, { "@type": "MedicalWebPage", "name": "Aurora kinase C", "alternateName": "Aurora Kinase C", "url": "https://questionsmedicales.fr/mesh/D064108", "about": { "@type": "MedicalCondition", "name": "Aurora kinase C", "code": { "@type": "MedicalCode", "code": "D064108", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.103.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Aurora kinases", "alternateName": "Aurora Kinases", "code": { "@type": "MedicalCode", "code": "D064127", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Karen Schindler", "url": "https://questionsmedicales.fr/author/Karen%20Schindler", "affiliation": { "@type": "Organization", "name": "Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA." } }, { "@type": "Person", "name": "Cecilia S Blengini", "url": "https://questionsmedicales.fr/author/Cecilia%20S%20Blengini", "affiliation": { "@type": "Organization", "name": "Department of Genetics; Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States of America." } }, { "@type": "Person", "name": "Mansour Aboelenain", "url": "https://questionsmedicales.fr/author/Mansour%20Aboelenain", "affiliation": { "@type": "Organization", "name": "Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA." } }, { "@type": "Person", "name": "Jing Wang", "url": "https://questionsmedicales.fr/author/Jing%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Oncology, the First Affiliated Hospital of Gannan Medical College, Ganzhou, China." } }, { "@type": "Person", "name": "Tao Guo", "url": "https://questionsmedicales.fr/author/Tao%20Guo", "affiliation": { "@type": "Organization", "name": "Department of Thoracic surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The molecular interaction of six single-stranded DNA aptamers to cardiac troponin I revealed by docking and molecular dynamics simulation.", "datePublished": "2024-05-15", "url": "https://questionsmedicales.fr/article/38748685", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0302475" } }, { "@type": "ScholarlyArticle", "name": "Identification and Molecular Mechanism of Novel Immunomodulatory Peptides from Gelatin Hydrolysates: Molecular Docking, Dynamic Simulation, and Cell Experiments.", "datePublished": "2023-02-07", "url": "https://questionsmedicales.fr/article/36748803", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.jafc.2c06982" } }, { "@type": "ScholarlyArticle", "name": "Discovery of novel targets and mechanisms of MEK inhibitor Selumetinib for LGG treatment based on molecular docking and molecular dynamics simulation.", "datePublished": "2022-05-06", "url": "https://questionsmedicales.fr/article/35523987", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00894-022-05132-9" } }, { "@type": "ScholarlyArticle", "name": "Insights into the binding mechanism between α-TOH and CYP4F2: A homology modeling, molecular docking, and molecular dynamics simulation study.", "datePublished": "2023-03-15", "url": "https://questionsmedicales.fr/article/36924012", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcb.30391" } }, { "@type": "ScholarlyArticle", "name": "The Inhibitory Potential of 2'-dihalo Ribonucleotides against HCV: Molecular Docking, Molecular Simulations, MM-BPSA, and DFT Studies.", "datePublished": "2022-07-15", "url": "https://questionsmedicales.fr/article/35889402", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/molecules27144530" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-Serine-Threonine Kinases", "item": "https://questionsmedicales.fr/mesh/D017346" }, { "@type": "ListItem", "position": 6, "name": "Aurora kinases", "item": "https://questionsmedicales.fr/mesh/D064127" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Aurora kinases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Aurora kinases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Aurora kinases", "description": "Comment diagnostiquer une anomalie des kinases Aurora ?\nQuels marqueurs sont associés aux kinases Aurora ?\nLes kinases Aurora sont-elles liées à des cancers spécifiques ?\nQuels tests sont utilisés pour évaluer l'activité des kinases Aurora ?\nPeut-on détecter les kinases Aurora dans le sang ?", "url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Molecular+Docking+Simulation&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Aurora kinases", "description": "Quels symptômes sont liés à une dysrégulation des kinases Aurora ?\nLes kinases Aurora affectent-elles la division cellulaire ?\nY a-t-il des signes précoces de cancer liés aux kinases Aurora ?\nLes kinases Aurora sont-elles impliquées dans des symptômes neurologiques ?\nComment les kinases Aurora influencent-elles la croissance tumorale ?", "url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Molecular+Docking+Simulation&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Aurora kinases", "description": "Peut-on prévenir les anomalies des kinases Aurora ?\nLes dépistages réguliers aident-ils à détecter les problèmes liés aux kinases Aurora ?\nY a-t-il des facteurs de mode de vie influençant les kinases Aurora ?\nLes antioxydants aident-ils à prévenir les anomalies des kinases Aurora ?\nLes vaccinations peuvent-elles prévenir les cancers liés aux kinases Aurora ?", "url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Molecular+Docking+Simulation&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Aurora kinases", "description": "Quels traitements ciblent les kinases Aurora ?\nLes inhibiteurs de kinases Aurora sont-ils efficaces ?\nQuels effets secondaires peuvent résulter des traitements ciblant les kinases Aurora ?\nLes traitements ciblant les kinases Aurora sont-ils combinés avec d'autres thérapies ?\nY a-t-il des essais cliniques sur les kinases Aurora ?", "url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Molecular+Docking+Simulation&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Aurora kinases", "description": "Quelles complications peuvent survenir avec des anomalies des kinases Aurora ?\nLes anomalies des kinases Aurora augmentent-elles le risque de métastases ?\nComment les anomalies des kinases Aurora affectent-elles le pronostic ?\nLes complications des traitements ciblant les kinases Aurora sont-elles fréquentes ?\nLes anomalies des kinases Aurora peuvent-elles affecter la réponse immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Molecular+Docking+Simulation&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Aurora kinases", "description": "Quels sont les facteurs de risque associés aux anomalies des kinases Aurora ?\nL'âge influence-t-il le risque d'anomalies des kinases Aurora ?\nLe tabagisme est-il un facteur de risque pour les kinases Aurora ?\nL'alimentation joue-t-elle un rôle dans les anomalies des kinases Aurora ?\nLes infections virales sont-elles liées aux anomalies des kinases Aurora ?", "url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Molecular+Docking+Simulation&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des kinases Aurora ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de tissus tumoraux peuvent révéler des anomalies." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux kinases Aurora ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux d'expression des kinases Aurora A et B peuvent servir de marqueurs tumoraux." } }, { "@type": "Question", "name": "Les kinases Aurora sont-elles liées à des cancers spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent surexprimées dans des cancers comme le sein et le poumon." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des kinases Aurora ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de phosphorylation et des analyses de Western blot sont couramment utilisés." } }, { "@type": "Question", "name": "Peut-on détecter les kinases Aurora dans le sang ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, la détection se fait principalement dans les tissus tumoraux, pas dans le sang." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une dysrégulation des kinases Aurora ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon le cancer, mais peuvent inclure fatigue, douleur et perte de poids." } }, { "@type": "Question", "name": "Les kinases Aurora affectent-elles la division cellulaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles jouent un rôle clé dans la mitose, et leur dysfonction peut entraîner des anomalies cellulaires." } }, { "@type": "Question", "name": "Y a-t-il des signes précoces de cancer liés aux kinases Aurora ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes précoces peuvent inclure des changements inexpliqués dans le corps, mais sont souvent vagues." } }, { "@type": "Question", "name": "Les kinases Aurora sont-elles impliquées dans des symptômes neurologiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un lien entre les kinases Aurora et des troubles neurologiques dans certains cancers." } }, { "@type": "Question", "name": "Comment les kinases Aurora influencent-elles la croissance tumorale ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elles régulent la mitose, et leur surexpression peut conduire à une croissance tumorale incontrôlée." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des kinases Aurora ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode spécifique, mais un mode de vie sain peut réduire le risque de cancer." } }, { "@type": "Question", "name": "Les dépistages réguliers aident-ils à détecter les problèmes liés aux kinases Aurora ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages réguliers peuvent aider à détecter des cancers associés aux anomalies des kinases." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de mode de vie influençant les kinases Aurora ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et l'exercice peuvent influencer la santé cellulaire et réduire les risques." } }, { "@type": "Question", "name": "Les antioxydants aident-ils à prévenir les anomalies des kinases Aurora ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que les antioxydants peuvent réduire le stress oxydatif, mais des recherches sont nécessaires." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles prévenir les cancers liés aux kinases Aurora ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancers spécifiques." } }, { "@type": "Question", "name": "Quels traitements ciblent les kinases Aurora ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques des kinases Aurora sont en développement pour traiter divers cancers." } }, { "@type": "Question", "name": "Les inhibiteurs de kinases Aurora sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent qu'ils peuvent réduire la croissance tumorale, mais des recherches sont nécessaires." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent résulter des traitements ciblant les kinases Aurora ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure nausées, fatigue et troubles hématologiques." } }, { "@type": "Question", "name": "Les traitements ciblant les kinases Aurora sont-ils combinés avec d'autres thérapies ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent combinés avec la chimiothérapie ou la radiothérapie pour améliorer l'efficacité." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques sur les kinases Aurora ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques évaluent l'efficacité des inhibiteurs de kinases Aurora dans divers cancers." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies des kinases Aurora ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la progression rapide du cancer et la résistance aux traitements." } }, { "@type": "Question", "name": "Les anomalies des kinases Aurora augmentent-elles le risque de métastases ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une surexpression des kinases Aurora est souvent associée à une augmentation des métastases." } }, { "@type": "Question", "name": "Comment les anomalies des kinases Aurora affectent-elles le pronostic ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont souvent liées à un pronostic défavorable en raison de la croissance tumorale agressive." } }, { "@type": "Question", "name": "Les complications des traitements ciblant les kinases Aurora sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications comme des infections et des troubles sanguins peuvent survenir." } }, { "@type": "Question", "name": "Les anomalies des kinases Aurora peuvent-elles affecter la réponse immunitaire ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent altérer la réponse immunitaire, rendant le corps moins efficace contre le cancer." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque associés aux anomalies des kinases Aurora ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux de cancer, l'exposition à des agents cancérigènes." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'anomalies des kinases Aurora ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'anomalies des kinases Aurora augmente généralement avec l'âge." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque pour les kinases Aurora ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs types de cancer associés aux kinases." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans les anomalies des kinases Aurora ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en graisses et en sucres peut augmenter le risque de cancer et d'anomalies." } }, { "@type": "Question", "name": "Les infections virales sont-elles liées aux anomalies des kinases Aurora ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le HPV, sont associées à des cancers où les kinases Aurora sont impliquées." } } ] } ] }

Sources (10000 au total)

The molecular interaction of six single-stranded DNA aptamers to cardiac troponin I revealed by docking and molecular dynamics simulation.

Cardiac troponin I (cTnI) is a cardiac biomarker for diagnosing ischemic heart disease and acute myocardial infarction. Current biochemical assays use antibodies (Abs) due to their high specificity an...

Identification and Molecular Mechanism of Novel Immunomodulatory Peptides from Gelatin Hydrolysates: Molecular Docking, Dynamic Simulation, and Cell Experiments.

The purpose of this study was to identify donkey-hide gelatin-derived immunomodulatory peptides targeting Toll-like receptor 4-myeloid differentiation 2 (TLR4-MD2) and elucidate their binding modes us...

Discovery of novel targets and mechanisms of MEK inhibitor Selumetinib for LGG treatment based on molecular docking and molecular dynamics simulation.

Based on molecular docking and molecular dynamics simulation, to find a new target and mechanism of MEK inhibitor Selumetinib in the treatment of low-grade glioma (LGG), and to provide theoretical gui...

Insights into the binding mechanism between α-TOH and CYP4F2: A homology modeling, molecular docking, and molecular dynamics simulation study.

α-Tocopherol (α-TOH) is a potent antioxidant. The concentrations of α-TOH in plasma are closely related to human health. α-TOH can be regulated by the metabolism of cytochrome P450 4F2 (CYP4F2). Howev...

Computational investigations of potential inhibitors of monkeypox virus envelope protein E8 through molecular docking and molecular dynamics simulations.

The World Health Organization (WHO) has declared the monkeypox outbreak a public health emergency, as there is no specific therapeutics for monkeypox virus (MPXV) disease. This study focused on dockin...

Bisbenzylisoquinolines from Cissampelos pareira L. as antimalarial agents: Molecular docking, pharmacokinetics analysis, and molecular dynamic simulation studies.

Malaria is a major global health issue due to the emergence of resistance to most of the available antimalarial drugs. There is an urgent need to discover new antimalarials to tackle the resistance is...

Exploration of Flavonoids as Lead Compounds against Ewing Sarcoma through Molecular Docking, Pharmacogenomics Analysis, and Molecular Dynamics Simulations.

Ewing sarcoma (ES) is a highly malignant carcinoma prevalent in children and most frequent in the second decade of life. It mostly occurs due to t(11;22) (q24;q12) translocation. This translocation en...

Potential Therapeutic Agents on Alzheimer's Disease through Molecular Docking and Molecular Dynamics Simulation Study of Plant-Based Compounds.

Globally Alzheimer's disease (AD) is a highly complex, heterogeneous, and multifactorial neurological disease. AD is categorized clinically through a steady loss in memory and progressive decline of c...

Inhibitory effect of lupeol, quercetin, and solasodine on Rhizopus oryzae: A molecular docking and dynamic simulation study.

Mucormycosis is an infection caused by fungi belonging to the order Mucorales. Rhizopus oryzae is one of the most prevalent organisms identified in mucormycosis patients. Because it spreads quickly th... The Rhizopus oryzae RNA-dependent RNA polymerase (RdRp) was the target for the design of drugs against the deadly mucormycosis. The three-dimensional structure of the RdRp was modelled with a Swiss mo... The RdRp protein binds strongly to lupeol (-7.2 kcal/mol), quercetin (-9.1 kcal/mol), and solasodine (-9.6 kcal/mol), according to molecular docking assessment based on the lowest binding energy, conf... The molecular docking and MD simulation investigation improved our understanding of phytochemical-RdRp interactions. Due to its high affinity for RdRp, solasodine may be a better treatment option for ...